Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 CAD | -1.05% | -1.73% | -7.81% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
Sales 2024 * | 35M 25.58M | Sales 2025 * | 38.7M 28.29M | Capitalization | 98.65M 72.1M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 2.82 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
15.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.46% |
Latest transcript on BioSyent Inc.
1 day | -1.05% | ||
1 week | -1.73% | ||
Current month | -1.16% | ||
1 month | -0.93% | ||
3 months | -2.19% | ||
6 months | +6.38% | ||
Current year | -7.81% |
Managers | Title | Age | Since |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 8.5 | -1.05% | 2,200 |
24-05-09 | 8.59 | +0.94% | 2,600 |
24-05-08 | 8.51 | -1.62% | 1,207 |
24-05-07 | 8.65 | +1.65% | 1,100 |
24-05-06 | 8.51 | -1.62% | 2,432 |
Delayed Quote Toronto S.E., May 10, 2024 at 03:46 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.81% | 72.2M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- RX Stock